[HTML][HTML] Emerging topical and systemic JAK inhibitors in dermatology
F Solimani, K Meier, K Ghoreschi - Frontiers in immunology, 2019 - frontiersin.org
Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …
[HTML][HTML] Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies
X Gong, X Chen, ME Kuligowski, X Liu, X Liu… - American journal of …, 2021 - Springer
Background Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib …
transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib …
JAK inhibitors in the treatment of atopic dermatitis
R Chovatiya, AS Paller - Journal of Allergy and Clinical Immunology, 2021 - Elsevier
Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …
presentation and often immense patient burden. Safe, targeted treatment options are …
[HTML][HTML] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
L Hoisnard, B Lebrun-Vignes, S Maury, M Mahevas… - Scientific Reports, 2022 - nature.com
Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …
[HTML][HTML] Targeting the Janus kinase family in autoimmune skin diseases
Autoimmune skin diseases are characterized by significant local and systemic inflammation
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
ME Dowty, TH Lin, MI Jesson, M Hegen… - Pharmacology …, 2019 - Wiley Online Library
Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various
inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function …
inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function …
[HTML][HTML] Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
N Nezamololama, K Fieldhouse, K Metzger… - Drugs in …, 2020 - ncbi.nlm.nih.gov
The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and
tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and …
tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and …
Treatment of alopecia universalis with topical Janus kinase inhibitors–a double blind, placebo, and active controlled pilot study
L Bokhari, R Sinclair - International Journal of Dermatology, 2018 - Wiley Online Library
Abstract Background Oral Janus kinase (JAK) inhibitors are currently being investigated in
phase II and phase III clinical trials for several inflammatory skin diseases including alopecia …
phase II and phase III clinical trials for several inflammatory skin diseases including alopecia …
Selective JAK inhibitors in development for rheumatoid arthritis
P Norman - Expert opinion on investigational drugs, 2014 - Taylor & Francis
Introduction: The JAK kinases are a family of four tyrosine receptor kinases that play a
pivotal role in cytokine receptor signalling pathways via their interaction with signal …
pivotal role in cytokine receptor signalling pathways via their interaction with signal …
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
Objectives Review of efficacy and safety of Janus kinase (JAK) inhibition in immune-
mediated inflammatory diseases (IMIDs). Methods A systematic literature research (SLR) of …
mediated inflammatory diseases (IMIDs). Methods A systematic literature research (SLR) of …